Skip to main content
Log in

Response to: comment on “Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections”

  • Letter to the Editor
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Wright KD, Panetta JC, Onar-Thomas A et al (2015) Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections. Cancer Chemother Pharmacol 75:27–35

    Article  CAS  PubMed  Google Scholar 

  2. Cohen I (2004) Defining the appropriate dosage of folinic acid after high-dose methotrexate for childhood acute lymphocytic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system. J Pediatr Hematol Oncol 26:156–163

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Karen D. Wright.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wright, K.D., Stewart, C.F. Response to: comment on “Delayed methotrexate excretion in infants and young children with primary central nervous system tumors and postoperative fluid collections”. Cancer Chemother Pharmacol 75, 877–878 (2015). https://doi.org/10.1007/s00280-015-2699-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-015-2699-6

Keywords

Navigation